Obesity study: Aleniglipron
Official title Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
ClinicalTrials.gov ID: NCT07654361
What this study is testing
What is Aleniglipron?
This is an investigational oral medicine being studied as a potential treatment for obesity.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if aleniglipron helps people lose weight and stay healthy over a long time, and to check its safety and side‑effects.
- Who it's for
- It is looking for adults who are overweight or obese and have a health condition related to their weight.
- What's involved
- Participants will take a pill once a day for about 76 weeks while following a lower‑calorie diet and more exercise. They will have regular visits for health checks and blood tests.
- Time commitment
- The study lasts about 76 weeks, with scheduled visits throughout to monitor weight, health, and any side‑effects.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 79
You may be able to join if
- Signed informed consent
- BMI ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) and presence of ≥1 of the obesity related comorbidities.
You likely can't join if
- Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes.
- Self-reported change in body weight \>5 kg within 3 months before Screening.
- Have prior or planned surgical or non-surgical treatment for obesity.
- Have or plan to have endoscopic and/or device-based therapy for obesity.
- Have obesity induced by other endocrine disorders.
- Impaired renal function at Screening
See the full eligibility criteria
- Signed informed consent
- BMI ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) and presence of ≥1 of the obesity related comorbidities.
- Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes.
- Self-reported change in body weight \>5 kg within 3 months before Screening.
- Have prior or planned surgical or non-surgical treatment for obesity.
- Have or plan to have endoscopic and/or device-based therapy for obesity.
- Have obesity induced by other endocrine disorders.
- Impaired renal function at Screening
- Chronic malabsorption
The study team makes the final eligibility decision.
Where it is enrolling
- Clearwater, Florida, United States
- Honolulu, Hawaii, United States
- Silver Spring, Maryland, United States
- Mankato, Minnesota, United States
- Richfield, Minnesota, United States
- Hazelwood, Missouri, United States
- St Louis, Missouri, United States
- Charlotte, North Carolina, United States
- Wilmington, North Carolina, United States
- Columbus, Ohio, United States
- Portland, Oregon, United States
- Austin, Texas, United States
- Renton, Washington, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 79 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Clearwater, Florida, United States; Honolulu, Hawaii, United States; Silver Spring, Maryland, United States; Mankato, Minnesota, United States; Richfield, Minnesota, United States; Hazelwood, Missouri, United States and 7 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.